VOX Vox Valor Capital Limited

RNS Number:3167V
VASTox plc
23 April 2007

                                   VASTox plc
                          ("VASTox" or "the Company")


  VASTOX PLC ANNOUNCES APPOINTMENT OF GEORGE ELLIOTT TO THE BOARD OF DIRECTORS


Oxford, UK, 23 April 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, announces today the appointment of George Elliott to the Board of
Directors as a Non-executive Director.


Mr Elliott, 54, brings to VASTox a wealth of financial and commercial expertise
and experience, gained from a 30-year career during which he has overseen the
financial development and growth of small technology companies into main-market
FTSE listed companies.


For seven years prior to joining VASTox's Board, Mr Elliott was Chief Financial
Officer of Wolfson Microelectronics plc, a leading global provider of high
performance semiconductors to the consumer electronics market with blue-chip
multinational customers that include Apple, Sony, Microsoft, Samsung and HP.
During his period, he oversaw the Company gain an entry into the FTSE 250 index.
Before his time with Wolfson, Mr Elliott was Business Development Director at
McQueen International Ltd (now SYKES), where he was responsible for strategic
sales and marketing.


Mr Elliott, formerly a partner of Grant Thornton, is a Chartered Accountant and
has a degree in Accountancy and Finance from Heriot-Watt University.


From July 2007, one of Mr Elliott's key roles on the Board will be to Chair the
Company's Audit Committee.


Barry Price, PhD, Chairman of VASTox, commented: "I am delighted to welcome a
man of George's calibre to VASTox's Board of Directors.  The financial knowledge
he brings complements and enhances the Board's existing range of skills and
expertise across all areas of business and will be invaluable as the Company
enters its next phase of growth and development."



George Elliott added "I am excited to be joining such a dynamic and ambitious
company as VASTox and I look forward to playing my role in helping the Company
fulfil its tremendous potential by building upon its progress already made and
deliver real value to all our shareholders."



AIM Rules Disclosure



Save for the disclosures below, there are no other disclosures to be under Rule
17 and paragraph (g) of Schedule 2 of the AIM rules.



Current Directorships
Company                                           Date of Appointment
Elliott Corporate Development Limited                   10 April 1996


Previous Directorships
Company                                           Date of Resignation
Wolfson  Microelectronics plc                        28 February 2007



Mr Elliott was a director of Calluna Technology Limited ("CTL"), a subsidiary of
Calluna plc, from 1998. He handed in his notice of resignation on 21 July 1999.
In February 2000, CTL appointed an administrator. At that time CTL had external
debts of #5.4 million and intergroup debts of #31.9 million.



                                    - ends -





For more information please contact:


VASTox

Steven Lee, PhD, Chief Executive Officer                Tel: +44 (0)1235 443951
Darren Millington, ACMA, Chief Financial Officer


Citigate Dewe Rogerson                                  Tel: +44 (0)207 638 9571
Mark Swallow / David Dible / Valerie Auffray


About VASTox plc



VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.



VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.



VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.



The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX



Further information about the company is available at www.vastox.com



This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections.



Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAPUUGGCUPMUBW

Grafico Azioni Vox Valor Capital (LSE:VOX)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Vox Valor Capital (LSE:VOX)
Storico
Da Giu 2023 a Giu 2024